Ethical Overkill: Institutions should take a unified look at protections for research on human subjects
By Editorial,
Nature
| 12. 09. 2014
The most important resource needed to conduct research on humans, it is said, is not brainpower or money: it is trust. In the United States, as elsewhere, hundreds of institutions and thousands of investigators work to protect that trust by carefully evaluating proposals for clinical trials and other research that uses human subjects.
Each US institution hosting such a study typically conducts its own ethical review of the proposal. The review process serves many functions: it is an expression of the responsibility that these investigators feel towards protecting their local community, an opportunity to tweak protocols to adapt to the community’s specific needs, and a protection against potential lawsuits resulting from a flawed research protocol.
Sadly, evidence suggests that much of this effort is misplaced. A 2010 survey of 45 institutions reviewing the same protocol found that local scrutiny resulted in no substantial changes (B. Ravina et al. Ann. Neurol. 67, 258–260; 2010). Instead, most alterations simply inserted standardized institutional language — unrelated to the proposed study — to the informed-consent document signed by research participants before they...
Related Articles
By Parmy Olson, Bloomberg Opinion | 07.12.2024
Photo from Hubert Burda Media via Flickr licensed under CC by NC-SA 2.0
Peter Thiel’s Enhanced Games promise to be an annual sporting event that lets athletes use performance-enhancing drugs, nicknamed the pro-doping Olympics (which some would scoff isn’t all...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Isabelle Bartram
| 07.17.2024
Image by Kuzzat Altay from Unsplash
Uyghurs, a predominantly Muslim minority in China, are mainly located in the autonomous region of Xinjiang. The Chinese government has pursued an aggressive settlement policy in this region since 1949, with the percentage of Han Chinese in the region increasing from five to forty percent in the second half of the 20th century. Since 2014, the Uyghurs have been subject to persecution and re-education – various sources have estimated that at least one million...
By Emma McDonald Kennedy
| 07.11.2024
Louise Perry’s recent article in The Spectator cautions against “The quiet return of eugenics,” a threat she locates in preimplantation genetic testing for polygenic disorders. The technology is billed as a way for parents undergoing IVF to select which embryo to implant based on information about each embryo’s genetic risk factors and traits. These reports, she says, give parents “a very full picture of the adult that embryo could become”––from their child’s risk of developing different diseases to their “likely...